Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026)].

Wiener klinische Wochenschrift·2026

Same author

[Lipids - Diagnostics and treatment in diabetes mellitus (Update 2026)].

Wiener klinische Wochenschrift·2026

Same author

[Cardiovascular diseases and heart failure in diabetes: diagnostics and management (Update 2026)].

Wiener klinische Wochenschrift·2026

Same author

[Hospital diabetes management (Update 2026)].

Wiener klinische Wochenschrift·2026

Same author

[Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)].

Wiener klinische Wochenschrift·2023

Same author

[Lipids-Diagnosis and therapy in diabetes mellitus (Update 2023)].

Wiener klinische Wochenschrift·2023

Search research articles

Related Experiment Video

Updated: May 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Lipid lowering therapy in type 2 diabetes.

Bernhard Föger¹

¹Department of Internal Medicine, Hospital Bregenz, Bregenz, Austria. bernhard.foeger@lkhb.at

Wiener Medizinische Wochenschrift (1946)

|July 20, 2011

Summary

Lowering LDL-cholesterol (LDL-C) is crucial for managing type 2 diabetes, despite counterintuitive lipoprotein profiles. Statin therapy effectively reduces cardiovascular risk in diabetic patients, with specific goals for those with and without atherosclerosis.

Area of Science:

Cardiology
Endocrinology
Metabolic Disorders

Background:

Type 2 diabetes is characterized by insulin resistance, leading to abnormal lipoprotein transport including high triglycerides, small dense LDL, and low HDL.
Despite a lipoprotein profile that might not suggest high LDL-cholesterol (LDL-C), clinical trials demonstrate the importance of LDL-C lowering in diabetic patients.

Purpose of the Study:

To outline evidence-based strategies for managing dyslipidemia in patients with type 2 diabetes.
To define LDL-C and Non-HDL-cholesterol (NHDL-C) goals for diabetic patients with and without established cardiovascular disease.

Main Methods:

Review of approximately 20 years of statin trials involving over 18,000 diabetic patients.
Analysis of treatment strategies including statin monotherapy, high-intensity statins, and combination therapies (statin with ezetimibe, niacin, or fenofibrate).

Related Experiment Videos

Last Updated: May 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Consideration of adjunctive therapies like pioglitazone for persistent dyslipidemia.

Main Results:

Patients without manifest atherosclerosis should aim for LDL-C <100 mg/dl or NHDL-C <130 mg/dl, often achievable with standard-intensity statins.
Patients with manifest coronary heart disease (CHD) require more aggressive treatment, targeting LDL-C <70 mg/dl or NHDL-C <100 mg/dl, frequently necessitating high-intensity statins or combination therapy.
Evidence for HDL-raising therapies is currently less robust than for LDL-lowering interventions.

Conclusions:

Prioritizing LDL-C reduction is a cornerstone of cardiovascular risk management in type 2 diabetes.
Treatment intensity should be tailored based on the presence of atherosclerosis, with combination therapies considered when goals are unmet.
While HDL-raising therapies are being explored, LDL-lowering remains the primary focus.